[Hemopoietic stem cell transplantation in lymphogranulomatosis].
Twenty patients with resistant and relapsed Hodgkin's disease were included into this investigation. The treatment effectiveness and regimen-related toxicity of BEAM-protocol were evaluated. Stem cell transplantation (SCT) was carried out either as bone marrow transplantation (BMT) in 11 patients or peripheral blood stem cell transplantation (PBSCT) in 9 patients. A comparison of the results pointed to a significant decrease in neutropenia duration, fewer blood transfusions needed and shorter stay in hospital in the PBSCT group. Complete remission was observed in 90% of patients of the SCT group, 91%-in BMT and 89%-PBSCT groups. It was found that high-dose chemotherapy followed by SCT is more effective in the treatment of resistant and relapsed Hodgkin's disease and, in certain situations, it is a treatment of choice. As to the toxicity of BEAM-protocol, it does not exceed those of the other chemotherapy modalities used in SCT.
Uss
A L
AL
Milanovich
N F
NF
Snegir'
V M
VM
Skriagin
A E
AE
Zmachinskiĭ
V A
VA
Batan
Z E
ZE
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001803:Blood Transfusion; D002330:Carmustine / Q000009:adverse effects; D002648:Child; D003561:Cytarabine / Q000009:adverse effects; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007902:Length of Stay; D008297:Male; D008558:Melphalan / Q000009:adverse effects; D011034:Podophyllotoxin / Q000009:adverse effects; D012008:Recurrence; D016896:Treatment Outcome
D003561:Cytarabine; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine